FRANKLIN, Tenn. — Peerbridge Health today announced FDA 510(k) clearance of Peerbridge Cor MDx, the next generation of its ambulatory ECG wearable. Cor MDx records continuous, multi-channel ECG for up to 14 days for review by clinicians, and it is the foundation on which the company is building its cardiac intelligence platform. Cor MDx is commercially available now and replaces the company’s first-generation Cor device.
The launch reflects Peerbridge’s broader mission to move cardiac care upstream. Cardiac decline is not a single event. It emerges across interconnected mechanisms: electrical, structural, functional, hemodynamic, and neurohormonal. Today those mechanisms are assessed with isolated tools that produce episodic snapshots, lack connectivity to one another, and rarely reach a patient before an acute event occurs.
Peerbridge believes the next era of cardiac care will be defined by earlier visibility, smarter escalation, and more connected decision-making across care environments, supported by high-fidelity physiologic data that follows the patient from hospital or emergency department discharge through recovery at home and follow-up in clinic.